Eli Lilly and Company, LLY is in the exchange NYSE and its industry is Drug Manufacturers – Major in the sector of Healthcare. Based in USA, Eli Lilly and Company, LLY has a market cap of 89930.41. Since its IPO date on the 6/1/1972, Eli Lilly and Company, LLY performance year to date is -0.61%. Today Eli Lilly and Company, LLY has gained 0.76%, with a current price of 82.09.
Ownership of the company is 11.40% for insider ownership while institutional ownership is 77.00%. The management of the company have seen the company have a payout ratio of 91.20%. Return of assets are at 6.90%, with return on investment at 9.50%.
In terms of debt levels and profit levels, Eli Lilly and Company, LLY is seeing a long-term debt/equity of 0.59. While Total debt/equity is 0.64. With a profit margin of 12.00%, this is combined with a gross margin of 73.70%, and operating margin of 14.60%. Eli Lilly and Company ability to meet debt levels, with a current ratio of 1.5, while the quick ratio is 1.1.
For the last year Eli Lilly and Company, LLY has seen a EPS growth of 1.60%. A performance for the year of 0.60%. The 52-week high is -5.01%, and the 52-week low is 22.52%. The average volume for Eli Lilly and Company, LLY is 4233000.
With a target price of 97.6, can Eli Lilly and Company, LLY reach this target? Looking at the value indicators of Eli Lilly and Company, LLY. Eli Lilly and Company has a P/E of 35.38 and a forward P/E of 20.09. Perhaps the more useful indicator than P/E, is PEG which has a value of 2.69. Eli Lilly and Company also has a P/S and a P/B of 4.36 and 5.93 respectively. For P/cash, Eli Lilly and Company has a value of 22.86, while it is *TBA for P/free cash flow.
At the current price of 82.09, Eli Lilly and Company has a dividend yield of 2.49%. We see a return on equity of 16.60%.
Looking more long-term Eli Lilly and Company, is projected to get an EPS growth for the next five years of 13.17%. In the short-term an EPS growth of 13.91% in the next year is forecasted. This is after a EPS growth of 1.60% for this year and for the last five years a -13.20% growth has been seen.